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LIST OF ABBREVIATIONS  
Ab: antibody 
APC: antigen presenting cell 
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CD86: cluster of differentiation 86 
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IMF: inflammatory maturation factor 
IL: interleukin 
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mDC: mature dendritic cell 
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NP: nanoparticle 
PBMC: peripheral blood mononuclear cells 
PBS: phosphate buffered saline 
PEG: polyethylene glycol 
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TMF: tolerogenic maturation factor 
TNF: tumor necrosis factor 







I. Abstract [41] 
Dendritic Cells (DCs) have shown great potential in a variety of immunotherapeutic 
applications due to their key role in both the innate and adaptive immune response. This study 
aims to observe the activation and phenotypic changes within the cell population following 
treatment with a variety of gold nanoparticles (AuNPs).  
AuNPs are currently being used as drug delivery vehicles, regulators and suppressors of the 
host immune response. They have easily modified surface chemistry and display high 
biocompatibility.  
Developing mechanisms to specifically manipulate DCs utilizing biomaterials will allow for 
a number of immunotherapeutic approaches to become available to patients suffering from 
autoimmune diseases such as HIV/AIDS, and cancer.   
Following treatment with numerous AuNP treatments varying in surface coating and 
concentration cells should demonstrate no abnormal death or patterns within the cell cycle and 












Nanoparticles (NPs) have become an increasingly investigated subject within the scientific 
community due to their high potential as a treatment option for cancer and numerous other 
diseases originating within and impacting the immune system. Research continues to broaden as 
investigators attempt to obtain a clearer understanding of NP characteristics and how to most 
effectively utilize their immunotherapeutic potentials.  
NPs demonstrate functionality in many applications such as drug delivery and release, 
immune response modulation, and diagnostic imaging. NP characteristics that are of interest are 
material, size, shape, and physicochemical surface alterations such as PEGylation or autologous 
serum-based coating. These specific characteristics exhibit precise control over NP function, and 
the research being conducted within this proposal specifically explores NP uptake by dendritic 
cells (DCs) and the subsequent impact NP treatments have on the activation state and phenotypic 
responses of DCs. DCs are antigen presenting cells (APCs) that play a distinct role in both the 
innate and adaptive immune response. An area still requiring further study is the impact that NPs 
could potentially have on the phenotypic profiles seen throughout the DC differentiation process.  
Gold nanoparticle (AuNP) samples have been prepared in the Wilhelm Lab at the University 
of Oklahoma in different sizes and coatings that will allow for manipulation and observation of 
DC phenotype. Maturation and tolerogenic markers were both fluorescently labeled to quantify 
expression following NP treatment. Fluorescent labelling has also been used to normalize 
collected data to the proportion of the cell population consisting only of DCs. Observing 
phenotypic trends will allow for further development and improvement of biomaterial systems to 
modulate host immune response with increased efficacy. Ultimately, this work is expected to 
result in the development of therapeutic treatment options for patients suffering from 




















Literature Review [41] 
1. Innate and Adaptive immunity  
There are two types of immunity that protect every distinction of vertebrates: the innate 
and adaptive immune systems. The innate immune response acts as the first line of defense 
against foreign entities which is often achieved by marking foreign entities with activation 
fragments [1]. These fragments have the potential to be identified by phagocytes for destruction 
of foreign cells [2, 3]. The adaptive response is composed of a set of plasma proteins that can 
bind to pathogen surfaces leading to proteolytic cleavage, whose fragments mediate an 
inflammatory response, recognition of pathogens by phagocytes, and finally results in lysis of the 
cell via membrane attack complex (MAC) [4, 5]. The recognition of pathogens by these 
phagocytes results in cytokine and chemokine release, attracting monocytes and neutrophils 
which will infiltrate infected tissues and initiate the inflammatory response [6].  
2. Dendritic Cells 
Dendritic Cells (DCs) are antigen presenting cells (APCs) that are activated to mediate a 
host immune response. They play an integral role in both innate and adaptive immunity via their 
role in T cell activation. The primary functions of DCs are capturing and presenting antigens and 
other foreign bodies to other cells within the immune system. In order to accomplish this, DCs 
phagocytize antigens, process them internally, and present the resulting antigen peptide on their 
cell surface. DCs are located in nearly all tissues and organs including the lymphoid organs. The 
contribution of DCs concerning the stimulation of specific T cell responses has shown potential 
in developing new vaccine strategies for the treatment of a number of different ailments, 
including infections, allergic and autoimmune diseases, and cancer [7].  
DCs originate from myeloid progenitor cells in the bone marrow which have the ability to 
differentiate into many different cell types. Monocytes are produced daily, on the order of 
multiple millions, and normally circulate through the bloodstream for a brief period of time 
before apoptosing spontaneously [8]. However, during an innate immune response, cytokines 
and chemokines excreted by leukocytes recruit monocytes to the site of inflammation [9]. At the 
site of inflammation, the monocytes will permeate the tissues and differentiate into immature 
dendritic cells (iDCs) when in the presence of granulocytemacrophage colony-stimulating factor 
(GM- CSF) and interleukin-4 (IL-4) [10]. Initially, chemoattractants resulting from tissue 
damage, pathogens products, and inflammatory cytokines attract iDCs to the site of infection. 
iDCs phagocytize antigens, degrade them via endocytosis, and produce antigenic peptides 
capable of binding to major histocompatibility complex class I (MHC I) and MHC II molecules. 
Following synthesis and expression of these molecules on the DC cell surface, the phenotype of 
the cell changes from an iDC to a mature dendritic cell (mDC).  
The function of the DC also changes from capturing antigens to presenting them, 
denoting them as antigen presenting cells (APCs). mDCs lack responsiveness to inflammatory 
chemokines and demonstrate responsiveness to lymphoid chemokines. Lymphoid chemokines 
will influence their migration to the draining lymph node [11]. Once they have infiltrated the 
lymph nodes, DCs conduct physical interactions with T cells to activate, or suppress, the 
adaptive immune response.  
3. Gold Nanoparticles 
Nanoparticles (NPs) are defined as an object within the range of 1-100nm in size. The 
function and use of nanoparticles are innumerable with precise control over the material, size, 
shape, surface chemistry, and treatment concentration. Concerning immunotherapies, gold 
nanoparticles (AuNPs) have been found to be effective due to their stability, solubility, particle 
size, and affinity to attach surface molecules [12]. This control can be utilized to allow AuNPs to 
function as antigen carriers, which can stimulate antigen presentation when phagocytized by 
iDCs. Using different surface coatings and growth factor treatments the maturation of the iDCs 
can by controlled and observed throughout the differentiation process. This process is not well 
understood and requires further revision considering all facets of engineering AuNP treatments. 
AuNPs have been shown to migrate to the lymph nodes when they are within the 20-200nm 
range [13]. Within this size range, larger particles demonstrate a decrease in the quantity of 
captured AuNPs. Lower sizes were also shown to be effective, demonstrating increased 
expression of proinflammatory genes in conjunction with minimal cytotoxicity when compared 
to silver NPs. Through numerous optimization trials, the 60nm gold particles were determined to 
be the most effective compromise between size and material [14, 15, 16].  
Though studies have determined the optimal AuNP size, concentration of cell treatments 
and particle surface alterations require further elucidation. Increasing the concentration of 
AuNPs have shown correlation with an increase in cytotoxicity, while lower concentrations have 
shown decreases in the quantity of uptake particles [17, 18]. Additional studies have observed 
surface chemistry correlations to NP uptake, however, the role of maturation in this process still 
remains unclear [19]. In order to understand and optimize the process in which iDCs differentiate 
into either mDCs or tDCs, more research must be done to elucidate the impact of treatment 
concentration and surface modifications to the particles being used.  
 
Methods and Materials [41]  
1. Cell Collection and Isolation 
Cells will be collected via whole blood collection at STAMPS Healthcare Center at Georgia 
Institute of Technology by a certified phlebotomist in accordance with protocol H15072 and 
associated informed consent documentation.  
Following the successful collection of whole blood from a donor, monocytes will be isolated 
from the sample, washed, and prepared for differentiation through growth factor treatments 
throughout the culture period. Whole blood will be diluted two-fold with phosphate buffered 
saline (PBS), and then this diluted mixture will be centrifuged in lymphocyte separation media 
(LSM). This centrifuge period will spin down the red blood cells from the sample, and leave a 
supernatant composed of monocytes and plasma components.  
 
2. Counting Cells  
Cells will be counted with one of two methods. The most commonly used method within this 
laboratory is to count a small sample of cells (10uL of cells + media) suspended in Isoton II 
electrolyte solution. The sample will be analyzed using the Multisizer 4e in the Cellular Analysis 
and Spectroscopy Core in the Petite institute. If this machine is unavailable, the cells will be 
counted using conventional hemacytometer techniques with a one-to-one dilution of cell 
suspension with trypan blue. They are then counted beaneath a microscope and resuspended to 
the desired concentration after being centrifuged once again.  
 
3. Human Cell Culture 
Monocytes isolated from the whole blood draw will be cultured in tissue-culture treated 
polystyrene plates (5.0E5 cells/mL) in complete RPMI-1640 media containing 10% fetal bovine 
serum (FBS) and 10% penicillin/streptomyocin (PEN/STREP). The cells will also be treated 
with Interleukin-4 (IL-4) as well as granulocytemacrophage colony-stimulating factor (GM- 
CSF) to induce proper differentiation of monocytes into DCs. This treatment with fresh, pre-
warmed media, IL-4, and GM-CSF will be repeated on the fifth day of treatment with the 
preparation of control groups.  
Control groups will include iDCs, mDCs, tDCs. To stimulate the DCs to further differentiate 
into different phenotypes a fraction of the initial population will undergo two different 
treatments. To stimulate DCs to differentiate into mDCs, cells are treated with LPS (50 U/uL) in 
conjunction with IL-4 and GM-CSF. Subsequently, tDCs will be stimulated by equal treatment 
with interleukin-10 (IL-10) and Interferon Alpha (INF-a).  
These three sets of controls: iDCs, mDCs. tDCs, will be prepared and transferred and seeded 
into a sterile 96-well, tissue-culture treated, microplate. The remainder of the wells within the 
plate will then be seeded with a combination of twelve different biomaterial treatments. These 
treatments will adjust the surface coating of the biomaterial in conjunction with a range of 
concentrations.  
 
4. Human Serum Extraction [41] 
Between day 0 and day 4 of DC culture, whole blood was collected from the same consenting 
donor as day 0 at STAMPS phlebotomy laboratory in accordance with protocol H10011 of 
H15072 approved by the IRB at the Georgia Institute of Technology. The blood was allowed to 
clot for 30 minutes at 25o C and centrifuged at 2000g for 10 minutes. The resultant supernatant 
contained a pellet of red blood cells and serum. The serum was extracted manually with an 
automatic pipette and stored at 0o C until used for NP preparation on day 5.  
 
5. Gold Nanoparticle Treatment Preparation [41] 
Gold nanoparticles were kindly supplied by the Wilhelm Lab at University of Oklahoma at 60nm 
and 5nM as stock solutions containing Bare, PEG-2K coated and PEG-5K coated particles. Bare 
nanoparticles were suspended in ultrapure water and PEGylated AuNPs were suspended in PBS 
in their respective stock solutions [20].  
Bare, PEG-2K and PEG-5K coated AuNP treatment preparation 
32 μL of each stock solution were prepared; two samples of the bare AuNP stock were prepared, 
one for bare AuNP treatment and a second for the serum-coated AuNP treatment group. The four 
samples were centrifuged for 35 minutes at 1200g to pellet the AuNPs, then each was washed 
twice with sodium citrate tribasic dehydrate solution (200 μL, 5 mM), centrifuging samples for 
35 minutes at 1200g and aspirating the supernatant after each wash. The resulting AuNP pellets 
of one of the bare AuNP samples, the PEG-2K AuNP aliquot and the PEG-5K AuNP aliquot 
were resuspended in 1 mL RPMI media, for an AuNP treatment sample concentration of 160 
pM. A serial dilution was performed on these three of the aliquots to obtain three concentrations 
(160 pM, 16 pM, and 1.6 pM) for each AuNP coating type.  
Serum-coated AuNP treatment preparation 
The pellet in the remaining sample of bare AuNPs was resuspended in 40 μL of chilled PBS, and 
added to an Eppendorf tube containing 400 μL of human serum (filtered with a 0.22 μm PES 
filter). The AuNPs were incubated in human serum for 1 hour with 95% relative humidity and 
5% CO2 at 37◦C. After incubation, the serum-AuNP solution was centrifuged for 35 min at 
1200g and the supernatant was aspirated. The serum-coated AuNPs were washed with chilled 
PBST twice by adding 750 ul of chilled PBST, centrifuging for 35 min at 1200g, and aspirating 
the supernatant. After the second PBST wash, the serum-coated AuNPs were washed with 1 mL 
chilled PBS by the same process. The final serum-coated AuNP pellet was resuspended in 1 mL 
RPMI media, for an AuNP treatment sample concentration of 160 pM. A serial dilution was 
performed to obtain three concentrations:160 pM, 16 pM, and 1.6 pM.  
 
6. Treatment of iDCs with Gold Nanoparticles in HTP Format [41] 
On day 5 of DC culture, NP treatments were prepared as described in section 4.2.3. Loosely 
adherent and non-adherent iDCs were harvested and resuspended in DC media with 1000 U/ml 
GM-CSF and 800 U/ml IL-4 at 5x105 DCs/ml. 100 μL of iDCs at a concentration of 5 x 105 
DCs/ml were plated onto each well in the 96-well tissue culture plate (Corning). The wells for 
the negative control of iDCs remained untreated, the wells for the positive control of mDCs were 
treated with LPS (1 mg/mL; E. coli 055:B5; Sigma), and the wells for the positive control of 
tDCs were treated with human IL-10 (3,500 U/mL; R&D Systems) and human IFN-alpha 
(35,000 U/mL; R&D Systems). 150 μl of each concentration group for each AuNP coating 
treatment group were added to different wells of the 96-well plate containing iDCs, such that the 
final concentration of AuNPs in each well were 0.1 pM, 1.0 pM and 10 pM (Figure 1). The iDCs 
were then incubated with the control, bare AuNP, PEG-2K coated AuNP, PEG-5K coated AuNP, 
and serum coated AuNP treatments for 24 hours with 95% relative humidity and 5% CO2 at 
37◦C.  
On day 6, the DCs treated in the 96-well plate were transferred directly to wells of a 96-well 
black filter plate wetted with PBS. The supernatants were removed by centrifuging the filter 
plate for 4 minutes at 400rpm. To each well, 100 μl of cold working fixation solution (0.05 % 
paraformaldehyde) was added, and the plate was incubated for at least 30 min at room 
temperature on a microplate shaker at 450 rpm.  
(VWR, West Chester, PA) followed by the removal of the fixative by centrifugation (4 minutes, 
400 rpm). Subsequently, DCs were stained with antibodies for surface marker expression, 
namely, anti-DC-SIGN-FITC (Clone 120507; R & D Systems), anti-CD86- PE (Clone BU63; 
Ancell) and anti-ILT3-AF647 (Clone ZM4.1, Biolegend). For isotype staining for background 
fluorescence elimination, the following antibodies were used: IgG2B-FITC (clone 133303; R&D 
Systems), IgG1-PE (clone MOPC31C; Ancell) and IgG1κ (clone MOPC-21; Biolegend) (Figure 
1).  
 
Figure 1. Layout of AuNP-DC treatments in 96-well plate. AuNP concentrations of 0.1 pM, 1.0 pM 
and 10 pM were added to DCs in individual wells for all AuNP treatment groups (bare, serum 
coated, PEG-2K coated, and PEG-5K coated AuNPs). Antibody staining was added to three of the six 
wells used for each treatment, and isotype staining was added to the other three wells.  
 
The plate was incubated in a plate shaker (600 rpm) at 40oC for 40 minutes protected from light. 
After this staining procedure, DCs were washed three times with washing solution of 0.1% BSA 
and 2mM EDTA in PBS, pH 7.20 by centrifugation at 400 RCF for 4 min. Afterwards, 100 μl of 
the washing solution was added to DCs and the fluorescence of each treatment group were 
measured. The geometric mean fluorescent intensities were measured with a Tecan Infinite F500 
microplate reader (Tecan US, Durham, NC) using excitation filters of 535/25 and 485/20 and the 
emission filters of 590/20 and 535/25, for PE and FITC, respectively, and 650/668 for anti-ILT3 
- AF647.  
The surface marker, CD86, is a costimulatory molecule for which expression becomes up-
regulated upon DCs maturation. Dendritic Cell-Specific Intercellular adhesion molecule-3-
Grabbing Non-integrin (DC-SIGN) is an endocytic receptor which expression is not significantly 
down-regulated upon DCs maturation. Immunoglobulin- like transcript 3 (ILT3) is an inhibitory 
receptors which expression is up-regulated upon anti-inflammatory (tolerogenic) DC response. 
The ratio of respective geometric mean fluorescent intensities for CD86 expression divided by 
DC-SIGN expression defines the metric of “inflammatory maturation factor” (IMF) as an indicator 
of pro-inflammatory DC phenotype. The ratio of respective geometric mean fluorescent intensities 
for ILT3 expression divided by CD86 expression defines the metric of “tolerogenic maturation 
factor” (TMF) as an indicator of tDC phenotype.  
 
7. Cellular Analysis  
Cells will be analyzed using fluorescent imagine in a high-throughput format within the 
Petite Institute at Georgia Tech.  
Initially, cells will be prepared for analysis using standard fixation techniques with 4.0% 
formaldehyde solution prepared in the lab using paraformaldehyde and PBS. This solution is 
then pH balanced to 7.1. Cells will then be transferred to a 96-well filtration plate, which will 
allow for treatments and washing cycles to be conducted more efficiently. Following fixation, 
cells will be stained with an antibody panel that will allow for proper identification of only the 
DC population (DCSIGN), and then also stained with markers to identify cell populations 
according to their surface receptors: mDCs (CD86) and tDCs (ILT-3). This staining will happen 
in a dark environment, while being shaken at 450 RPM at 4o Celsius.  
Once cells are stained, they fluorescence intensity will be measured using a micro-plate 
reader within the lab. This plate reader will measure the fluorescence at nine different locations 
within each well to account for variability in cell seeding, as well as precise pipetting. The plate 
reader will take these measurements automatically, and then a statistical analysis will be 
conducted on the raw data to compare the proportions of each cell type relative to the overall 
population.  
In addition to this analysis, observations will be made to determine the impact of biomaterial 
treatment with the different coatings and concentrations on the NPs used to treat the DCs. Trends 
and effective treatments will lead to further modulation of the materials, and further study within 
in vivo models. 
 
Results 
DCs Treated with Serum Coated Particles Exhibited Highest Tolerogenic Maturation Expression 
[41] 
The TMF, as defined by the ratio of the geometric mean fluorescent intensities for ILT3/CD86, 
was determined for each AuNP coating type and concentration. As expected, the DCs treated 
with IL-10 and IFN-alpha to act as the positive tDC control had a significantly higher TMF than 
both the iDC and mDC controls, and the mDC control had a very low TMF (Figure 2). The TMF 
for the tDC control was higher than DCs treated with any concentration of bare, PEG-2K, or 
PEG-5K coated AuNPs. However, all concentrations of the serum-coated AuNP treatments 
showed a higher TMF than any other treatment group, including the tDC control. The PEG-5K 
coated AuNP treatment group of DCs had TMFs that were lower than the iDC control for AuNP 
concentrations 0.1 pM and 10 pM; at 1 pM, the TMF was higher than that of the iDC control. 
The bare AuNP treatment, serum coated AuNP treatment, and PEG-2K treatment showed a 
slight concentration dependence with increasing concentrations of AuNPs and an increased 
TMF. 
  
Figure 2. Tolerogenic maturation factor (ILT3/CD86) of DCs treated with AuNPs with mean ± range, n=2 
donors. Treatments of different AuNP coatings (bare, serum, PEG-2K, PEG-5K) and concentrations (0.1 pM, 
1.0 pM, 10 pM) were used. DCs were incubated with AuNP treatments for 24 hours at 37°C. DCs were 
stained with antibodies for surface marker expression, stained with isotype for background and geometric 
mean fluorescent intensities were determined for ILT3 and CD86 expression for each treatment group using 
a Tecan Infinite F500 microplate reader.  
 
Inflammatory maturation factor expression showed concentration dependence for DCs treated 
with bare AuNPs and serum-coated AuNPs [41] 
The IMF, as defined by the ratio of the geometric mean fluorescent intensities for 
CD86/DCSIGN, was determined for each AuNP coating type and concentration. As expected, 
the positive control for inflammatory DC maturation (mDC) had the highest IMF, and the 
positive control for tolerogenic DC maturation (tDC) had the lowest IMF. DCs treated with the 
bare AuNP treatment group showed a strong positive correlation with increasing bare AuNP 
concentration and an increased IMF. The reverse trend was seen with the serum coated AuNP 
treatment group, where increasing concentrations of serum coated AuNPs were correlated to a 
decrease in the IMF. This apparent concentration dependence for the serum coated AuNPs was 
seen with the TMF as well, with increasing concentrations of AuNPs correlating to an increased 
TMF. 
 
Figure 3. Inflammatory maturation factor (CD86/DCSIGN) of DCs treated with AuNPs with mean ± range, 
n=2 donors. Treatments of different AuNP coatings (bare, serum, PEG-2K, PEG-5K) and concentrations (0.1 
pM, 1.0 pM, 10 pM) were used. DCs were incubated with AuNP treatments for 24 hours at 37°C. DCs were 
stained with antibodies for surface marker expression, stained with isotype for background and geometric 
mean fluorescent intensities were determined for CD86 and DCSIGN expression for each treatment group 
using a Tecan Infinite F500 microplate reader.  
 
Figure 4. Confirmation of successful DC culture results based on HTP and flow cytometry methodology. Cell 
populations cultured under standard techniques demonstrate proper ratios of maturation and tolerization 
over the course of 5 day culture. A-C demonstrate these results in the HTP format, and D-F confirm these 
results with higher specificity based on flow cytometry analysis.  
 
Discussion [41] 
The phenotype of DCs was differentially modulated by bare, serum-coated, PEG- 2K 
coated, and PEG-5K coated AuNPs. Specifically, serum coated AuNPs had the highest levels of 
TMF (ILT3/CD86) for all concentration groups (0.1 pM, 1.0 pM, 10 pM), and all concentrations 
of serum coated AuNPs were also higher than the TMF for the tDC control. Additionally, the 
serum coated AuNPs showed concentration dependence for both the TMF and IMF values; 
increasing the concentrations of serum coated AuNPs increased the TMF and decreased the IMF. 
This indicates that the interaction between serum coated AuNPs and DCs resulted in greater 
levels of ILT3 expression on the DCs and a tolerogenic phenotype. 
 The bare AuNPs also showed a concentration dependent effect but for IMF expression, 
where increasing bare AuNP concentrations showed an increased IMF. However, the IMFs for 
all bare AuNP concentrations were still lower than the positive control, mDC. These results 
indicate that in the presence of bare AuNPs, DC expression of CD86 increases, therefore causing 
an inflammatory, activated DC phenotype. The PEG-5K treatment group did not show 
concentration dependence for TMF, and the TMF values of all concentrations were closest to the 
iDC control. While concentration dependence was seen for PEG-5K coated AuNPs for IMF 
levels, these values were also closer to the iDC control than tDCs or mDCs. The PEG-2K coated 
AuNP treatment stayed within a similar range of TMFs and IMFs as the PEG-5K coated AuNP 
group. However, a slight concentration dependence was shown for the PEG-2K AuNP treatment 
for TMF, but not for IMF. These results indicate that the PEG-2K and PEG-5K AuNP coatings 
did not show a significant change in DC phenotype towards an activating or tolerogenic 
phenotype.  
It is important to note that this data was accumulated from only two donors. More trials 
are necessary to demonstrate the statistical significance of the trends observed in these 
preliminary results for bare and serum coated AuNPs, as well as to demonstrate that the 
PEGylated AuNPs did not have a significant effect on DC phenotype. Additionally, an 
assumption being made in the analysis of the data in this study is that the AuNPs are actually 
being phagocytized by the DCs, which may not necessarily be the case. Because this is an in 
vitro study, DCs may simply be interacting with serum molecules and NPs in solution because 
there is not a complicated matrix of additional molecules and cells that would be found in vivo.  
Figure 4 demonstrates corrections made to the DC culture setting have had a successful 
impact and demonstrate proper control results. These results suggested that AuNPs should be 
reincorporated into experimentation and that results obtained in future trials will be viable so 
long as these controls are replicated.  
Conclusions and Future Work 
 The continuation of this research did not generate new results with AuNPs incorporated 
into trials. The purpose of my contribution to this work was to reinstate successful DC culture 
into the Babensee Lab protocols with HTP methodology. A standstill was reached with 
successful DC culture that prevented viable results from being obtained to assess the impact of 
AuNPs on DCs. Ultimately, successful HTP has been obtained after minor corrections have been 
made to the culture process.  
 Furthermore, other undergraduates have been trained to successfully conduct DC culture 
in Babensee Lab going forward and will be incorporating NPs into future trials in semesters to 
come. The correction of HTP DC culture will have broad impacts on experimentation that is 
currently being developed and will allow for expedited production of results regarding the 
impact of biomaterials on DC populations.  
 Additionally, a protocol for HTP flow cytometry has been developed for an increase in 
specificity when observing immunofluorescence. This protocol was developed by Sommer 
Durham and I and will allow for HTP methodology to be maintained and continue to expedite 
results, as well as more accurate and repeatable results being obtained to characterize results 
from biomaterial applications on cell populations. This protocol will have a broad impact on all 
future work conducted in the Babensee Lab and is an exciting development from my time here.  
 Future work will include multiplex assays on DC culture supernatants to characterize the 
microenvironment in which cells have been cultured. This characterization will allow for a 
highly tuned approach to diseases originating in the immune system and lends to extensive 
development of biomaterial applications for further in vitro assessment. Additionally, the 
research conducted in this experiment will hopefully be scaled up to an in vivo model to assess 
physiological impact that biomaterial treatments can have on immune based diseases. Using the 
results generated from this study, a murine model for cancer, multiple sclerosis, or HIV/AIDS 
could be analyzed for benefit from biomaterial treatment. Additionally, drug delivery with the 
NPs used in this study should be assessed to identify the potential benefit on the aforementioned 
ailments. This will be possible due to the fact that DC culture has been successfully completed 
and will continue to be conducted in the Babensee Lab by future undergraduates Ayan Dasgupta 
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